FDA Inspection 1130798 — Philip NMI Raskin
The FDA completed an inspection of Philip NMI Raskin on September 4, 2020 in Dallas, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 4, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Dallas, TX (United States)
Additional Details
Clinical Investigator (CI)